SCYNEXIS, Inc.
(NASDAQ : SCYX)

( )
SCYX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
PTLAPortola Pharmaceuticals, Inc. -0.11%17.936.5%$167.21m
HZNPHorizon Therapeutics Plc -3.04%48.826.5%$144.10m
CTLTCatalent, Inc. 1.35%79.062.3%$137.76m
MYOKMyoKardia, Inc. -0.69%103.261.8%$131.39m
BHCBausch Health Cos., Inc. 1.06%19.130.0%$126.12m
VRXValeant Pharmaceuticals International, Inc. 1.06%19.1314.1%$112.56m
UTHRUnited Therapeutics Corp. 2.15%125.7014.3%$76.32m
ICPTIntercept Pharmaceuticals, Inc. 1.71%76.6716.8%$63.16m
ARGXargenx SE -1.02%230.340.0%$59.52m
JAZZJazz Pharmaceuticals Plc 0.74%118.742.4%$57.11m
GWPHGW Pharmaceuticals Plc 1.02%128.576.2%$54.50m
AMRNAmarin Corp. Plc -2.78%6.641.6%$51.62m
AXSMAxsome Therapeutics, Inc. -2.05%74.251.9%$46.44m
PRGOPerrigo Co. Plc -1.49%55.546.8%$42.66m
ICLRICON plc -0.85%169.484.3%$40.99m

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.